TF and neoplasm: Importantly, treatment with BEVs‐LCTP‐siSLC7A11 not only impaired tumorigenesis but also activated ferroptosis pathways, as evidenced by altered expression levels of SLC7A11 and transferrin in tumor and metastatic tissues.